CVS Health Corporation (CVS) Stock Price & How to Invest

CVS Health runs three reporting segments. Health Care Benefits is the Aetna insurance business, which earns premiums from roughly 26 million medical members and profits when claims (the medical benefit ratio) stay below what it collects. Health Services is built around the Caremark pharmacy benefit manager, which negotiates drug prices and manages pharmacy claims for health plans and employers and generated over $48 billion of revenue in Q1 2026. Pharmacy and Consumer Wellness is the familiar retail footprint of CVS drugstores, which makes money filling prescriptions and selling front-of-store health and consumer goods, with same-store prescription volumes up nearly 7% in Q1 2026.

The modern shape of the company traces to its 2018 acquisition of Aetna for roughly $70 billion, which combined a national insurer with the existing pharmacy and PBM businesses and added substantial debt. After a difficult stretch in 2023 and 2024 when Aetna's medical costs ran well above plan and the stock fell sharply, David Joyner became CEO in October 2024 and was later named board chair; he has framed the recovery as restoring pricing discipline at Aetna while running the integrated model more tightly. Total revenue now runs around $400 billion annually, among the largest of any U.S. company.

The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. The Caremark PBM faces intensifying regulatory and political pressure, including FTC litigation, a 2026 House Judiciary antitrust report, state investigations in Florida and elsewhere, and rebate pass-through reform that could compress a core profit pool. The retail pharmacy business faces reimbursement pressure and store closures, and the company carries a large debt balance from the Aetna deal that limits flexibility if the turnaround stalls.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see CVS Health Corporation's investor relations page or your broker.

• Revenue (annual run-rate): ~$400 billion; FY2026 guidance at least ~$405 billion
• Adjusted EPS (FY2026 guidance): ~$7.30 to $7.50 (Q1 2026 was ~$2.57)
• Aetna medical benefit ratio (Q1 2026): ~84.6%, improved from ~87.3% a year earlier
• Dividend yield: ~2.5% (~$2.66 annual, ~$0.665 quarterly)
• P/E ratio: ~46 trailing (depressed by prior charges); ~14 forward on guidance
• Market cap: ~$133 billion (shares ~$104)

CVS trades at a low forward earnings multiple versus the broad market, which reflects lingering caution after the 2023 to 2024 Aetna downturn rather than current results. The value angle rests on whether improving margins and ~$400 billion of revenue can support the raised guidance. Figures are approximate and tied to the asOf date; verify live quotes and the latest filings before acting.

There are three common ways to get CVS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so CVS sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where CVS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

CVS today is a vertically integrated healthcare company whose results swing most on Aetna's medical costs and the pace of the Joyner-era turnaround; Q1 2026 showed the recovery taking hold, with Aetna's medical benefit ratio improving to ~84.6% from ~87.3% a year earlier and the company raising full-year adjusted EPS guidance to ~$7.30 to $7.50. If you believe the integrated insurer-PBM-pharmacy model can earn durable margins again and that the stock's low valuation reflects past problems more than future ones, the question becomes sizing and overlap with the rest of your portfolio, not timing; the risk is that medical costs reaccelerate, PBM reform compresses a core profit pool, or the heavy debt load limits flexibility before the turnaround fully lands.

Whether CVS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CVS a buy?, and where the stock could go from here in the CVS stock forecast.

For income investors, whether CVS pays a dividend and how the payout looks is covered in does CVS pay a dividend?